Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma

British Journal of Clinical Pharmacology

Volumn 56, Issue 4, 2003, Pages 422-426

  Currie, Graeme P ^a   Lima, John J ^b   Sylvester, Jim E ^b   Lee, Daniel K C ^a   Cockburn, Wendy J R ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

Asthma; Bronchial hyperresponsiveness; Leukotriene receptor antagonist

Indexed keywords

ADENOSINE PHOSPHATE; CETIRIZINE; CORTICOSTEROID; FORMOTEROL; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; MONTELUKAST; NITRIC OXIDE; SALMETEROL; THEOPHYLLINE; TRIAMCINOLONE; ZAFIRLUKAST; BRONCHODILATING AGENT; DIAGNOSTIC AGENT; GLUTATHIONE TRANSFERASE; LEUKOTRIENE-C4 SYNTHASE; METHACHOLINE CHLORIDE;

ARTICLE; ASTHMA; BLOOD CELL; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; ENZYME POLYMORPHISM; EOSINOPHIL; EVALUATION; EXHALATION; FORCED EXPIRATORY VOLUME; GENOTYPE; GEOMETRY; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; WILD TYPE; BRONCHUS; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; INHALATION TEST; META ANALYSIS; PHYSIOLOGY;

ADENOSINE MONOPHOSPHATE; ASTHMA; BRONCHI; BRONCHIAL PROVOCATION TESTS; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; FORCED EXPIRATORY VOLUME; GLUTATHIONE TRANSFERASE; HUMANS; LEUKOTRIENE ANTAGONISTS; METHACHOLINE CHLORIDE; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 0141505006     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01952.x     Document Type: Article

References (26)

1. Salvi SS, Krishna MT, Sampson AP, et al. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001; 119: 1533-1546.
2. Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999; 353: 57-62.
3. 4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000; 23: 290-296.
4. Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55(Suppl 2): S28-S31.
5. Polosa R, Rorke S, Holgate ST. Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Thorax 2002; 57: 649-654.
6. Holgate ST. Adenosine provocation: a new test for allergic type airway inflammation. Am J Respir Crit Care Med 2002; 165: 317-318.
7. Wilson AM, Dempsey OJ, Sims EJ, et al. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001; 119: 1021-1026.
8. Lipworrh BJ, Dempsey OJ, Aziz I, et al. Effects of adding a leukotriene antagonist or a long-acting beta2-agonist in asthmatic patients with the glycine-16 beta (2)-adrenoceptor genotype. Am J Med 2000; 109: 114-121.
9. Sims EJ, Lipworth BJ. Sustained bronchoprotection with montelukast but not formoterol as add-on therapy in asthmatics with the homozygous glycine 16 beta2- adrenoceptor genotype. J Allergy Clin Immunol 2002; 109 (2): S157.
10. Currie GP, Lee DKC, Dempsey OJ, et al. A proof of concept study to evaluate putative benefits of montelukast in moderate persistent asthmatics. Br J Clin Pharmacol 2003; 55: 609-615.
11. Wilson AM, Dempsey OJ, Sims EJ, et al. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001; 31: 616-624.
12. Dempsey OJ, Kennedy G, Lipworth BJ. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol 2002; 109: 68-74.
13. Dempsey OJ, Fowler SJ, Wilson A, et al. Effects of adding either a leukotriene receptor antagonist or low dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002; 122: 151-159.
14. Wilson AM, Orr LC, Sims EJ, et al. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 2000; 162: 1297-1301.
15. Beach JR, Young CL, Avery AJ, et al. Measurement of airway responsiveness to methacholine: relative importance of the precision of drug delivery and the method of assessing response. Thorax 1993; 48: 239-243.
16. Tan KS, McFarlane LC, Lipworth BJ. Loss of normal cyclical beta2-adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. Thorax 1997; 52: 608-611.
17. Kharitonov SA, Chung KF, Evans D, et al. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med 1996; 153: 1773-1780.
18. Standardization of Spirometry 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
19. Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350: 1599-1600.
20. Asano K, Shiomi T, Hasegawa N, et al. Leukotriene C4 synthase gene A (-444) C polymorphism and clinical response to a CYS-LT (1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12: 565-570.
21. Currie GP, Haggart K, Lee DKC, et al. Effects of histamine and leukotriene antagonism on mannitol and adenosine monophosphate challenge. Clin Exp Allergy 2003; 33: 783-788
22. Currie GP, Lipworth BJ. Bronchoprotective effects of leukotriene receptor antagonists in asthma: a meta-analysis. Chest 2002; 122: 146-150.
23. Van Den Berge M, Meijer RJ, Kerstjens HA, et al. PC (20) adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than PC (20) methacholine. Am J Respir Crit Care Med 2001; 163: 1546-1550.
24. Dworski R, Fitzgerald GA, Oates JA, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 149: 953-959.
25. O'Shaughnessy KM, Wellings R, Gillies B, et al. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis 1993; 147: 1472-1476.
26. Currie GP, Lee DK, Haggart K, et al., Effects of montelukast on surrogate inflammatory markers in corticosteroid treated asthmatics. Am J Respir Crit Care Med 2003; 167: 1232-1238.